Dianthus Therapeutics, Inc. /DE/ business relationships
Companies named in Dianthus Therapeutics, Inc. /DE/’s 10-K filed 2026-03-09, and public companies whose annual reports name Dianthus Therapeutics, Inc. /DE/. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 80% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Dianthus Therapeutics, Inc. /DE/’s annual report 2
“On October 21, 2024, Zenas assigned the Zenas License Agreement to its affiliated entity, Zenas BioPharma (HK) Limited ("Zenas HK").” SEC filing
“In August 2019, the Company entered into a license agreement with Alloy Therapeutics, LLC ("Alloy").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.